SCHEMBL5465733

SCHEMBL5465733

CC1C(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)CN1C(c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 4/20 0.42
CRHR2 Q13324 4/20 0.42
SLC6A9 P48067 3/20 0.38
HSP90AA1 P07900 1/20 0.37
MAPK1 P28482 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
KMT2A Q03164 2/20 0.35
LMNA P02545 3/20 0.35
ALDH1A1 P00352 3/20 0.35
GAA P10253 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
APP P05067 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465740 1.00 CRHBP (0.42) CRHBPCRHR2SLC6A9HSP90AA1MAPK1
SCHEMBL5465728 1.00 CRHBP (0.42) CRHBPCRHR2SLC6A9HSP90AA1MAPK1
SCHEMBL5456288 0.87 CRHBP (0.46) CRHBPCRHR2SLC6A9HSP90AA1MAPK1
SCHEMBL5457578 0.87 CRHBP (0.46) CRHBPCRHR2SLC6A9HSP90AA1MAPK1
SCHEMBL5456287 0.87 CRHBP (0.46) CRHBPCRHR2SLC6A9HSP90AA1MAPK1
SCHEMBL5449815 0.86 CRHBP (0.47) CRHBPCRHR2HSP90AA1MAPK1MCOLN3
SCHEMBL14564673 0.86 CRHBP (0.47) CRHBPCRHR2HSP90AA1MAPK1MCOLN3
SCHEMBL5454728 0.86 CRHBP (0.47) CRHBPCRHR2HSP90AA1MAPK1MCOLN3
SCHEMBL14564677 0.84 CNR1 (0.42) CRHBPCRHR2SLC6A9KMT2AALDH1A1
SCHEMBL14564678 0.84 CRHBP (0.44) CRHBPCRHR2HSP90AA1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066587-A1 Substituted azetidine compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE S.A (ES) 2007-03-22 US claimed
EP-1718609-A1 SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-11-08 EP claimed
WO-2005077897-A1 SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2005-08-25 WO claimed
US-20050187208-A1 Substituted Azetidine compounds, their preparation and use as medicaments LABORATORIOS DE DR. ESTEVE S.A. (ES) 2005-08-25 US claimed
US-20070066587-A1 Substituted azetidine compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE S.A (ES) 2007-03-22 US disclosed
EP-1718609-A1 SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-11-08 EP disclosed
WO-2005077897-A1 SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2005-08-25 WO disclosed
US-20050187208-A1 Substituted Azetidine compounds, their preparation and use as medicaments LABORATORIOS DE DR. ESTEVE S.A. (ES) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066587-A1 Substituted azetidine compounds, their preparation and use as medicaments AZI2, NISCH, QDPR CRHBP 4443/4885CRHR2 3452/4885SLC6A9 1388/4885
US-20050187208-A1 Substituted Azetidine compounds, their preparation and use as medicaments AZI2, NISCH, QDPR CRHBP 4443/4885CRHR2 3452/4885SLC6A9 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.